HGF/c-Met Inhibition as Adjuvant Therapy Improves Outcomes in an Orthotopic Mouse Model of Pancreatic Cancer
Authors:
- Tony C. Y. PangTPTony C. Y. Pang
- Zhihong XuZXZhihong Xu
- Alpha Raj MekapoguAMAlpha Raj Mekapogu
- Srinivasa PothulaSPSrinivasa Pothula
- Therese BeckerTherese Becker
- Susan CorleySCSusan Corley
- Marc R. WilkinsMWMarc R. Wilkins
- David GoldsteinDGDavid Goldstein
- Romano PirolaRPRomano Pirola
- Jeremy WilsonJWJeremy Wilson
- Minoti ApteMAMinoti Apte
Open Access
Abstract
Background: Inhibition of hepatocyte growth factor (HGF)/c-MET pathway, a major mediator of pancreatic stellate cell (PSC)−PC cell interactions, retards local and distant cancer progression. This study examines the use of this treatment in preventing PC progression after resection. We further investigate the postulated existence of circulating PSCs (cPSCs) as a mediator of metastatic PC. Methods: Two orthotopic PC mouse models, produced by implantation of a mixture of luciferase-tagged human pancreatic cancer cells (AsPC-1), and human PSCs were used. Model 1 mice underwent distal pancreatectomy 3-weeks post-implantation (n = 62). One-week post-resection, mice were randomised to four treatments of 8 weeks: (i) IgG, (ii) gemcitabine (G), (iii) HGF/c-MET inhibition (HiCi) and (iv) HiCi + G. Tumour burden was assessed longitudinally by bioluminescence. Circulating tumour cells and cPSCs were enriched by filtration. Tumours of Model 2 mice progressed for 8 weeks prior to the collection of primary tumour, metastases and blood for single-cell RNA-sequencing (scRNA-seq). Results: HiCi treatments: (1) reduced both the risk and rate of disease progression after resection; (2) demonstrated an anti-angiogenic effect on immunohistochemistry; (3) reduced cPSC counts. cPSCs were identified using immunocytochemistry (α-smooth muscle actin+, pan-cytokeratin−, CD45−), and by specific PSC markers. scRNA-seq confirmed the existence of cPSCs and identified potential genes associated with development into cPSCs. Conclusions: This study is the first to demonstrate the efficacy of adjuvant HGF/c-Met inhibition for PC and provides the first confirmation of the existence of circulating PSCs.Keywords
Funding Information
- PanKind, The Australian Pancreatic Cancer Foundation (RG172336)
This publication has 57 references indexed in Scilit:
- Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transitionBMC Cancer, 2012
- Epidermal growth factor receptor and insulinlike growth factor 1 receptor expression predict poor survival in pancreatic ductal adenocarcinomaCancer, 2011
- Integrative annotation of human large intergenic noncoding RNAs reveals global properties and specific subclassesGenes & Development, 2011
- Malignant cells facilitate lung metastasis by bringing their own soilProceedings of the National Academy of Sciences, 2010
- Role of Pancreatic Stellate Cells in Pancreatic Cancer MetastasisThe American Journal of Pathology, 2010
- Pancreatic Stellate Cells: Partners in Crime with Pancreatic Cancer CellsCancer Research, 2008
- Cancer-Associated Stromal Fibroblasts Promote Pancreatic Tumor ProgressionCancer Research, 2008
- Rhamm−/− fibroblasts are defective in CD44-mediated ERK1,2 motogenic signaling, leading to defective skin wound repairJournal of Cell Biology, 2006
- Aberrant expression of tight junction-related proteins ZO-1, claudin-1 and occludin in synovial sarcoma: an immunohistochemical study with ultrastructural correlationLaboratory Investigation, 2004
- KEGG: Kyoto Encyclopedia of Genes and GenomesNucleic Acids Research, 2000